Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nuvalent, Inc. (NUVL : NSDQ)
 
 • Company Description   
Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 62

 
 • Price / Volume Information   
Yesterday's Closing Price: $42.50 Daily Weekly Monthly
20 Day Moving Average: 230,072 shares
Shares Outstanding: 56.82 (millions)
Market Capitalization: $2,414.88 (millions)
Beta: 1.44
52 Week High: $44.61
52 Week Low: $8.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.82% 5.66%
12 Week 54.71% 43.62%
Year To Date 42.71% 29.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
One Broadway 14thFloor
-
Cambridge,MA 02142
USA
ph: 857-357-7000
fax: -
chelcie@thrustsc.com http://www.nuvalent.com
 
 • General Corporate Information   
Officers
James R. Porter - Chief Executive Officer; President and Director
Alexandra Balcom - Chief Financial Officer and Treasurer
Emily Drabant Conley - Director
Andrew A. F. Hack - Director
Michael Meyers - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 670703107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/09/23
Share - Related Items
Shares Outstanding: 56.82
Most Recent Split Date: (:1)
Beta: 1.44
Market Capitalization: $2,414.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.44
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -22.22%
vs. Previous Quarter: 10.20%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/23 - -25.63
12/31/22 - -26.81
09/30/22 - -27.99
ROA
03/31/23 - -24.59
12/31/22 - -25.74
09/30/22 - -26.96
Current Ratio
03/31/23 - 26.81
12/31/22 - 24.54
09/30/22 - 18.90
Quick Ratio
03/31/23 - 26.81
12/31/22 - 24.54
09/30/22 - 18.90
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - 7.81
12/31/22 - 9.59
09/30/22 - 4.88
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©